Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 3/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 6/20 | 0.38 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6134778 | 0.85 | MCL1 (0.41) | PPARGMCL1PTPN5PTPN1POLB | |
| SCHEMBL6322473 | 0.85 | SCN9A (0.41) | SCN9APPARGMCL1PTPN5RAB9A | |
| SCHEMBL5881578 | 0.84 | PPARG (0.55) | PPARGMCL1CNR1 | |
| SCHEMBL6319665 | 0.83 | KDM4E (0.46) | SCN9APTPN5RAB9APOLB | |
| SCHEMBL5881907 | 0.83 | PPARG (0.54) | PPARGMCL1PTPN1CNR1 | |
| SCHEMBL5881789 | 0.83 | PPARG (0.54) | PPARGMCL1PTPN1CNR1 | |
| SCHEMBL6319251 | 0.83 | PTPN5 (0.52) | SCN9APPARGPTPN5RAB9ATLR8 | |
| SCHEMBL5882099 | 0.82 | PPARG (0.46) | PPARGMCL1PTPN5PTPN1CNR1 | |
| SCHEMBL6320738 | 0.82 | PPARG (0.46) | PPARGPTPN5PTPN1CNR1 | |
| SCHEMBL6134732 | 0.82 | MAPT (0.44) | PPARGMCL1PTPN5NR1H4POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171185-A1 | Indole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD., A JAPANESE CORPORATION | 2005-08-04 | — | — | US | claimed |
| EP-1070705-A1 | INDOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-24 | — | — | EP | claimed |
| US-20050171185-A1 | Indole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD., A JAPANESE CORPORATION | 2005-08-04 | — | — | US | disclosed |
| EP-1070705-A1 | INDOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171185-A1 | Indole derivatives | PDE5A, IGFBP5, HTR5A | SCN9A 1847/4885PPARG 2279/4885MCL1 3761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.